Skip to main content

Oncology

In the Literature, Oncology
Olaparib Maintenance Extends Progression-Free Survival in Advanced Ovarian Cancer
Read More
In the Literature, Oncology
Tisagenlecleucel Leads to High Rates of Durable Response in Relapsed, Refractory DLBCL
Read More
Multiple Myeloma, Oncology
Elotuzumab, Lenalidomide, and Dexamethasone Combination Demonstrates High Response Rate in High-Risk Smoldering Multiple Myeloma
Chase Doyle
Chase Doyle
Read More
Leukemia, Oncology
First-Line Ibrutinib Improves Outcomes Compared with Current Standard of Care in Older Patients with Chronic Lymphocytic Leukemia
Wayne Kuznar
Wayne Kuznar
Read More
Leukemia, Oncology
First-Line Enasidenib Achieves Complete Remission in Older Patients with Acute Myeloid Leukemia and IDH2 Mutation
Charles Bankhead
Charles Bankhead
Read More
Leukemia, Oncology
Researchers Identify First Mutation to Explain Resistance to Venetoclax
Phoebe Starr
Phoebe Starr
Read More
Immunotherapy, Oncology
Durable Responses to CAR T-Cell Therapy in B-Cell Lymphomas
Phoebe Starr
Phoebe Starr
Read More
Immunotherapy, Oncology
Explosive Development of BCMA CAR T-Cell Therapies for Multiple Myeloma
Phoebe Starr
Phoebe Starr
Read More
Immunotherapy, Oncology
Checkpoint Inhibitor a New Approach to Jump-Start a Waning Response to CAR T-Cell Therapy
Phoebe Starr
Phoebe Starr
Read More
Leukemia, Oncology
MURANO: Venetoclax-Rituximab at Fixed Duration Beats Chemo­immunotherapy in Relapsed/Refractory CLL
Phoebe Starr
Phoebe Starr
Read More
Page 11 of 27
Results 101 - 110 of 262